upadacitinib AD
Selected indexed studies
- A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. (N Engl J Med, 2025) [PMID:40174237]
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2021) [PMID:34347860]
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (N Engl J Med, 2023) [PMID:37224198]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (2023) pubmed
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2021) pubmed
- A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. (2025) pubmed
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. (2021) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. (2023) pubmed
- Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. (2023) pubmed
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. (2021) pubmed
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2021) pubmed
- Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). (2024) pubmed